» Articles » PMID: 26211626

The FHL2 Regulation in the Transcriptional Circuitry of Human Cancers

Overview
Journal Gene
Specialty Molecular Biology
Date 2015 Jul 28
PMID 26211626
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

The Four-and-a-half LIM (FHL)-only protein is a subfamily of protein members under the LIM-only protein family. These proteins are identified by their characteristic four and a half cysteinerich LIM homeodomain. Five members have been categorized into the FHL subfamily, which are FHL1, FHL2, FHL3, FHL4 and activator of CREM in testis (ACT) in human. FHL2 is amongst the most examined members within the family. Fhl2, the gene that code for the protein, is transcriptionally regulated by diverse types of transcription factors, for example, p53, serum response factor (SRF), and specificity protein 1 (Sp1). The expression of FHL2 is found in different tissues and organs and has been reported as a critical participant influencing the wide types of cancer such as breast cancer, gastrointestinal (GI) cancers, liver cancer and prostate cancer. The expression profile of FHL2 appeared to have a significant functional role in the carcinogenesis of these cancers which are mediated by different types of transcription factor including both tumor suppressors and inducers. In this review, we will first describe the molecular network governing FHL2 expression, which focus on the transcription factors conveying FHL2-initiated responses. In the second part, FHL2-linked cancers and the underlying molecular machinery will be discussed. Factors other than transcriptional regulation which may involve the cancer progression such as mutations of fhl2 and posttranslational modifications of the protein will also be mentioned.

Citing Articles

Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer.

Azam H, Veale C, Zitzmann K, Marcone S, Gallagher W, Prencipe M PLoS One. 2024; 19(12):e0309491.

PMID: 39671399 PMC: 11642960. DOI: 10.1371/journal.pone.0309491.


Ionising radiation exposure-induced regulation of selected biomarkers and their impact in cancer and treatment.

Mzizi Y, Mbambara S, Moetlhoa B, Mahapane J, Mdanda S, Sathekge M Front Nucl Med. 2024; 4:1469897.

PMID: 39498386 PMC: 11532091. DOI: 10.3389/fnume.2024.1469897.


FHL1: A novel diagnostic marker for papillary thyroid carcinoma.

Zeng Y, Zeng D, Qi X, Wang H, Wang X, Dai X Pathol Int. 2024; 74(9):520-529.

PMID: 39119938 PMC: 11551809. DOI: 10.1111/pin.13467.


Hsa-miR-92b-3p Targeting FHL2 to Enhance Radiosensitivity of Nasopharyngeal Carcinoma.

Zeng C, Duan S, Zhao L, Jiang J Biochem Genet. 2024; 63(1):713-729.

PMID: 38512583 DOI: 10.1007/s10528-024-10741-5.


FHL2 promotes the aggressiveness of lung adenocarcinoma by inhibiting autophagy via activation of the PI3K/AKT/mTOR pathway.

Wang S, Liu B, Su Y, Wang N, Dong P, Xu X Thorac Cancer. 2024; 15(8):630-641.

PMID: 38323374 PMC: 10928251. DOI: 10.1111/1759-7714.15234.


References
1.
Scholl F, McLoughlin P, Ehler E, De Giovanni C, Schafer B . DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol. 2000; 151(3):495-506. PMC: 2185594. DOI: 10.1083/jcb.151.3.495. View

2.
Kahl P, Gullotti L, Heukamp L, Wolf S, Friedrichs N, Vorreuther R . Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006; 66(23):11341-7. DOI: 10.1158/0008-5472.CAN-06-1570. View

3.
Turley E, Veiseh M, Radisky D, Bissell M . Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?. Nat Clin Pract Oncol. 2008; 5(5):280-90. PMC: 2846172. DOI: 10.1038/ncponc1089. View

4.
van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, HUBER H . Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene. 2009; 28(45):4022-33. PMC: 2900602. DOI: 10.1038/onc.2009.253. View

5.
Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, Kuhl M . The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J Cell Biol. 2002; 159(1):113-22. PMC: 2173499. DOI: 10.1083/jcb.200202075. View